Periorbital cellulitis: a comparison of different treatment regimens.
Periorbital cellulitis was retrospectively investigated in a cohort of 69 children, 1.5-16 years of age, who were admitted to Hacettepe University Children's Hospital. The aim of the study was to define the most important cause of the disease and to choose the most appropriate antimicrobial regimen. Sinusitis (43%) was found to be the most frequent disease associated with periorbital cellulitis. Trauma (25%) and odontogenic infections (6%) were the next most common predisposing causes. Staphylococcus aureus was isolated from 14 (74%) of 19 cultures. Two antibiotic combinations, penicillin plus chloramphenicol and sulbactam-ampicillin (SAM) with or without ornidazole was used in 30 (43%) and 39 (57%) of 69 cases, respectively. The duration of treatment with these two antibiotic combinations was generally between 7 and 10 days. No statistical difference was found between the two antibiotic combinations in the cure and recurrence rates but five (17%) of the 30 cases using penicillin plus chloramphenicol, and one (3%) of the 39 cases using SAM with or without ornidazole had recurrent periorbital cellulitis. It was concluded that SAM can be the first line of drug treatment for periorbital cellulitis as it is easily used in every age group and etiology (trauma, sinusitis, etc.). It provides total recovery and has less side effects and risk of recurrence. It also has a broad antimicrobial spectrum.
Kanra
G
G
Department of Pediatric Infectious Diseases, Hacettepe University Children's Hospital, Ankara, Turkey.
Seçmeer
G
G
Gönç
E N
EN
Ceyhan
M
M
Ecevit
Z
Z
D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002481:Cellulitis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009916:Orbital Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D010406:Penicillins / Q000627:therapeutic use; D012189:Retrospective Studies; D013407:Sulbactam / Q000627:therapeutic use; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D010406:Penicillins; D000667:Ampicillin; D013407:Sulbactam